Review



gradient-based nonlinear function minimisation tool matlab's fmincon function  (MathWorks Inc)


Bioz Verified Symbol MathWorks Inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    MathWorks Inc gradient-based nonlinear function minimisation tool matlab's fmincon function
    Gradient Based Nonlinear Function Minimisation Tool Matlab's Fmincon Function, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gradient-based nonlinear function minimisation tool matlab's fmincon function/product/MathWorks Inc
    Average 90 stars, based on 1 article reviews
    gradient-based nonlinear function minimisation tool matlab's fmincon function - by Bioz Stars, 2026-04
    90/100 stars

    Images



    Similar Products

    90
    KNIME GmbH gradient boosted regression tree technique generated with the knime tool
    Gradient Boosted Regression Tree Technique Generated With The Knime Tool, supplied by KNIME GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gradient boosted regression tree technique generated with the knime tool/product/KNIME GmbH
    Average 90 stars, based on 1 article reviews
    gradient boosted regression tree technique generated with the knime tool - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    90
    ArcSoft Inc gradient fill tool
    Gradient Fill Tool, supplied by ArcSoft Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gradient fill tool/product/ArcSoft Inc
    Average 90 stars, based on 1 article reviews
    gradient fill tool - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    90
    MIM Software Inc gradient-based technique (petedge + tool)
    Gradient Based Technique (Petedge + Tool), supplied by MIM Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gradient-based technique (petedge + tool)/product/MIM Software Inc
    Average 90 stars, based on 1 article reviews
    gradient-based technique (petedge + tool) - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    90
    MIM Software Inc gradient-based tool pet edge
    Gradient Based Tool Pet Edge, supplied by MIM Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gradient-based tool pet edge/product/MIM Software Inc
    Average 90 stars, based on 1 article reviews
    gradient-based tool pet edge - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    90
    MathWorks Inc gradient-based nonlinear function minimisation tool matlab's fmincon function
    Gradient Based Nonlinear Function Minimisation Tool Matlab's Fmincon Function, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gradient-based nonlinear function minimisation tool matlab's fmincon function/product/MathWorks Inc
    Average 90 stars, based on 1 article reviews
    gradient-based nonlinear function minimisation tool matlab's fmincon function - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    90
    Qlucore Inc xgboost (extreme gradient boosting, integrated tool
    Protein profiling of extracellular vesicles in relation to progression‐free survival. Extracellular vesicles (EVs) isolated from plasma samples from metastatic urothelial cancer (mUC) patients at day 21 were subjected to proximity extension assay (PEA) protein profiling with the Oncology II ® assay (see Section ). (A) Rank regression analyses of protein signatures in EVs related to progression‐free survival (PFS) [long (green) vs short (red)] of the study population. The qlucore software rank regression tool was used with P ≤ 0.05, and protein signatures were sorted without ( left panel ) or with ( right panel ) the number of EVs applied in the PEA profiling as elimination factor (see Section ). For description of the processing of the PEA data prior to the Qlucore analyses with respect to samples showing protein expression below lower limit of detection (LOD) see Sections and . The PEA data were also analysed with the <t>XGBoost</t> integrated tool of the qlucore software (see Section ). The proteins sorted out by this approach and that also were revealed by univariate rank regression analyses are indicated with (*). (B) The normalized protein expression (NPX) values of individual proteins from (A) were analysed in EVs from plasma of patients with short (≤ 138 days) or long (> 138 days) PFS ( top panel ) or after normalising for the number of EVs used in the PEA profiling ( bottom panel ). Only proteins that were statistically significant using t ‐test (see Section ) at P ≤ 0.05 and ≤ 0.06 are shown. Bars represent standard deviation (SD) values. Proteins that only showed significant association with PFS when non‐normalised PEA data were used are presented in Fig. . Please note that pat. #114 was excluded in these analyses. For LOD of the proteins, see Table . (C) The expression of individual proteins from the PEA analyses was plotted with linearised values against PFS in linear regression analyses (see Section ). The table indicates the Pearson correlation coefficient alongside P ‐value for non‐normalised samples. Please, note that pat. #114 was excluded in these analyses. Presented data in A–C are from one PEA profiling of one biological isolate of EVs from plasma of the individual patients. (D) Western blot profiling of SYND‐1 and GZMH in EVs isolated from plasma samples of mUC patients at day 21. SYND‐1 and GZMH were profiled without normalising for the amount of EVs in the different samples. The fold expression of SYND‐1 relative to pat. #107 is given with (fold norm) or without (fold) normalisation for the number of EVs analysed. The densitometric quantification of SYND‐1 (without normalisation) is presented in Fig. . Data shown are from one western blot analysis of one biological isolate of EVs from the individual plasma samples of the patients.
    Xgboost (Extreme Gradient Boosting, Integrated Tool, supplied by Qlucore Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/xgboost (extreme gradient boosting, integrated tool/product/Qlucore Inc
    Average 90 stars, based on 1 article reviews
    xgboost (extreme gradient boosting, integrated tool - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    90
    MathWorks Inc implementation of tool for computation of qmri gradients along anatomical axes of subcortical structures
    Protein profiling of extracellular vesicles in relation to progression‐free survival. Extracellular vesicles (EVs) isolated from plasma samples from metastatic urothelial cancer (mUC) patients at day 21 were subjected to proximity extension assay (PEA) protein profiling with the Oncology II ® assay (see Section ). (A) Rank regression analyses of protein signatures in EVs related to progression‐free survival (PFS) [long (green) vs short (red)] of the study population. The qlucore software rank regression tool was used with P ≤ 0.05, and protein signatures were sorted without ( left panel ) or with ( right panel ) the number of EVs applied in the PEA profiling as elimination factor (see Section ). For description of the processing of the PEA data prior to the Qlucore analyses with respect to samples showing protein expression below lower limit of detection (LOD) see Sections and . The PEA data were also analysed with the <t>XGBoost</t> integrated tool of the qlucore software (see Section ). The proteins sorted out by this approach and that also were revealed by univariate rank regression analyses are indicated with (*). (B) The normalized protein expression (NPX) values of individual proteins from (A) were analysed in EVs from plasma of patients with short (≤ 138 days) or long (> 138 days) PFS ( top panel ) or after normalising for the number of EVs used in the PEA profiling ( bottom panel ). Only proteins that were statistically significant using t ‐test (see Section ) at P ≤ 0.05 and ≤ 0.06 are shown. Bars represent standard deviation (SD) values. Proteins that only showed significant association with PFS when non‐normalised PEA data were used are presented in Fig. . Please note that pat. #114 was excluded in these analyses. For LOD of the proteins, see Table . (C) The expression of individual proteins from the PEA analyses was plotted with linearised values against PFS in linear regression analyses (see Section ). The table indicates the Pearson correlation coefficient alongside P ‐value for non‐normalised samples. Please, note that pat. #114 was excluded in these analyses. Presented data in A–C are from one PEA profiling of one biological isolate of EVs from plasma of the individual patients. (D) Western blot profiling of SYND‐1 and GZMH in EVs isolated from plasma samples of mUC patients at day 21. SYND‐1 and GZMH were profiled without normalising for the amount of EVs in the different samples. The fold expression of SYND‐1 relative to pat. #107 is given with (fold norm) or without (fold) normalisation for the number of EVs analysed. The densitometric quantification of SYND‐1 (without normalisation) is presented in Fig. . Data shown are from one western blot analysis of one biological isolate of EVs from the individual plasma samples of the patients.
    Implementation Of Tool For Computation Of Qmri Gradients Along Anatomical Axes Of Subcortical Structures, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/implementation of tool for computation of qmri gradients along anatomical axes of subcortical structures/product/MathWorks Inc
    Average 90 stars, based on 1 article reviews
    implementation of tool for computation of qmri gradients along anatomical axes of subcortical structures - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    90
    MathWorks Inc gradient descent optimization tools
    Protein profiling of extracellular vesicles in relation to progression‐free survival. Extracellular vesicles (EVs) isolated from plasma samples from metastatic urothelial cancer (mUC) patients at day 21 were subjected to proximity extension assay (PEA) protein profiling with the Oncology II ® assay (see Section ). (A) Rank regression analyses of protein signatures in EVs related to progression‐free survival (PFS) [long (green) vs short (red)] of the study population. The qlucore software rank regression tool was used with P ≤ 0.05, and protein signatures were sorted without ( left panel ) or with ( right panel ) the number of EVs applied in the PEA profiling as elimination factor (see Section ). For description of the processing of the PEA data prior to the Qlucore analyses with respect to samples showing protein expression below lower limit of detection (LOD) see Sections and . The PEA data were also analysed with the <t>XGBoost</t> integrated tool of the qlucore software (see Section ). The proteins sorted out by this approach and that also were revealed by univariate rank regression analyses are indicated with (*). (B) The normalized protein expression (NPX) values of individual proteins from (A) were analysed in EVs from plasma of patients with short (≤ 138 days) or long (> 138 days) PFS ( top panel ) or after normalising for the number of EVs used in the PEA profiling ( bottom panel ). Only proteins that were statistically significant using t ‐test (see Section ) at P ≤ 0.05 and ≤ 0.06 are shown. Bars represent standard deviation (SD) values. Proteins that only showed significant association with PFS when non‐normalised PEA data were used are presented in Fig. . Please note that pat. #114 was excluded in these analyses. For LOD of the proteins, see Table . (C) The expression of individual proteins from the PEA analyses was plotted with linearised values against PFS in linear regression analyses (see Section ). The table indicates the Pearson correlation coefficient alongside P ‐value for non‐normalised samples. Please, note that pat. #114 was excluded in these analyses. Presented data in A–C are from one PEA profiling of one biological isolate of EVs from plasma of the individual patients. (D) Western blot profiling of SYND‐1 and GZMH in EVs isolated from plasma samples of mUC patients at day 21. SYND‐1 and GZMH were profiled without normalising for the amount of EVs in the different samples. The fold expression of SYND‐1 relative to pat. #107 is given with (fold norm) or without (fold) normalisation for the number of EVs analysed. The densitometric quantification of SYND‐1 (without normalisation) is presented in Fig. . Data shown are from one western blot analysis of one biological isolate of EVs from the individual plasma samples of the patients.
    Gradient Descent Optimization Tools, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gradient descent optimization tools/product/MathWorks Inc
    Average 90 stars, based on 1 article reviews
    gradient descent optimization tools - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    96
    MathWorks Inc gradient-based optimization tool fmincon
    Protein profiling of extracellular vesicles in relation to progression‐free survival. Extracellular vesicles (EVs) isolated from plasma samples from metastatic urothelial cancer (mUC) patients at day 21 were subjected to proximity extension assay (PEA) protein profiling with the Oncology II ® assay (see Section ). (A) Rank regression analyses of protein signatures in EVs related to progression‐free survival (PFS) [long (green) vs short (red)] of the study population. The qlucore software rank regression tool was used with P ≤ 0.05, and protein signatures were sorted without ( left panel ) or with ( right panel ) the number of EVs applied in the PEA profiling as elimination factor (see Section ). For description of the processing of the PEA data prior to the Qlucore analyses with respect to samples showing protein expression below lower limit of detection (LOD) see Sections and . The PEA data were also analysed with the <t>XGBoost</t> integrated tool of the qlucore software (see Section ). The proteins sorted out by this approach and that also were revealed by univariate rank regression analyses are indicated with (*). (B) The normalized protein expression (NPX) values of individual proteins from (A) were analysed in EVs from plasma of patients with short (≤ 138 days) or long (> 138 days) PFS ( top panel ) or after normalising for the number of EVs used in the PEA profiling ( bottom panel ). Only proteins that were statistically significant using t ‐test (see Section ) at P ≤ 0.05 and ≤ 0.06 are shown. Bars represent standard deviation (SD) values. Proteins that only showed significant association with PFS when non‐normalised PEA data were used are presented in Fig. . Please note that pat. #114 was excluded in these analyses. For LOD of the proteins, see Table . (C) The expression of individual proteins from the PEA analyses was plotted with linearised values against PFS in linear regression analyses (see Section ). The table indicates the Pearson correlation coefficient alongside P ‐value for non‐normalised samples. Please, note that pat. #114 was excluded in these analyses. Presented data in A–C are from one PEA profiling of one biological isolate of EVs from plasma of the individual patients. (D) Western blot profiling of SYND‐1 and GZMH in EVs isolated from plasma samples of mUC patients at day 21. SYND‐1 and GZMH were profiled without normalising for the amount of EVs in the different samples. The fold expression of SYND‐1 relative to pat. #107 is given with (fold norm) or without (fold) normalisation for the number of EVs analysed. The densitometric quantification of SYND‐1 (without normalisation) is presented in Fig. . Data shown are from one western blot analysis of one biological isolate of EVs from the individual plasma samples of the patients.
    Gradient Based Optimization Tool Fmincon, supplied by MathWorks Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gradient-based optimization tool fmincon/product/MathWorks Inc
    Average 96 stars, based on 1 article reviews
    gradient-based optimization tool fmincon - by Bioz Stars, 2026-04
    96/100 stars
      Buy from Supplier

    90
    MIM Software Inc gradient search pet edge tool mim version 6.6tm
    Protein profiling of extracellular vesicles in relation to progression‐free survival. Extracellular vesicles (EVs) isolated from plasma samples from metastatic urothelial cancer (mUC) patients at day 21 were subjected to proximity extension assay (PEA) protein profiling with the Oncology II ® assay (see Section ). (A) Rank regression analyses of protein signatures in EVs related to progression‐free survival (PFS) [long (green) vs short (red)] of the study population. The qlucore software rank regression tool was used with P ≤ 0.05, and protein signatures were sorted without ( left panel ) or with ( right panel ) the number of EVs applied in the PEA profiling as elimination factor (see Section ). For description of the processing of the PEA data prior to the Qlucore analyses with respect to samples showing protein expression below lower limit of detection (LOD) see Sections and . The PEA data were also analysed with the <t>XGBoost</t> integrated tool of the qlucore software (see Section ). The proteins sorted out by this approach and that also were revealed by univariate rank regression analyses are indicated with (*). (B) The normalized protein expression (NPX) values of individual proteins from (A) were analysed in EVs from plasma of patients with short (≤ 138 days) or long (> 138 days) PFS ( top panel ) or after normalising for the number of EVs used in the PEA profiling ( bottom panel ). Only proteins that were statistically significant using t ‐test (see Section ) at P ≤ 0.05 and ≤ 0.06 are shown. Bars represent standard deviation (SD) values. Proteins that only showed significant association with PFS when non‐normalised PEA data were used are presented in Fig. . Please note that pat. #114 was excluded in these analyses. For LOD of the proteins, see Table . (C) The expression of individual proteins from the PEA analyses was plotted with linearised values against PFS in linear regression analyses (see Section ). The table indicates the Pearson correlation coefficient alongside P ‐value for non‐normalised samples. Please, note that pat. #114 was excluded in these analyses. Presented data in A–C are from one PEA profiling of one biological isolate of EVs from plasma of the individual patients. (D) Western blot profiling of SYND‐1 and GZMH in EVs isolated from plasma samples of mUC patients at day 21. SYND‐1 and GZMH were profiled without normalising for the amount of EVs in the different samples. The fold expression of SYND‐1 relative to pat. #107 is given with (fold norm) or without (fold) normalisation for the number of EVs analysed. The densitometric quantification of SYND‐1 (without normalisation) is presented in Fig. . Data shown are from one western blot analysis of one biological isolate of EVs from the individual plasma samples of the patients.
    Gradient Search Pet Edge Tool Mim Version 6.6tm, supplied by MIM Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gradient search pet edge tool mim version 6.6tm/product/MIM Software Inc
    Average 90 stars, based on 1 article reviews
    gradient search pet edge tool mim version 6.6tm - by Bioz Stars, 2026-04
    90/100 stars
      Buy from Supplier

    Image Search Results


    Protein profiling of extracellular vesicles in relation to progression‐free survival. Extracellular vesicles (EVs) isolated from plasma samples from metastatic urothelial cancer (mUC) patients at day 21 were subjected to proximity extension assay (PEA) protein profiling with the Oncology II ® assay (see Section ). (A) Rank regression analyses of protein signatures in EVs related to progression‐free survival (PFS) [long (green) vs short (red)] of the study population. The qlucore software rank regression tool was used with P ≤ 0.05, and protein signatures were sorted without ( left panel ) or with ( right panel ) the number of EVs applied in the PEA profiling as elimination factor (see Section ). For description of the processing of the PEA data prior to the Qlucore analyses with respect to samples showing protein expression below lower limit of detection (LOD) see Sections and . The PEA data were also analysed with the XGBoost integrated tool of the qlucore software (see Section ). The proteins sorted out by this approach and that also were revealed by univariate rank regression analyses are indicated with (*). (B) The normalized protein expression (NPX) values of individual proteins from (A) were analysed in EVs from plasma of patients with short (≤ 138 days) or long (> 138 days) PFS ( top panel ) or after normalising for the number of EVs used in the PEA profiling ( bottom panel ). Only proteins that were statistically significant using t ‐test (see Section ) at P ≤ 0.05 and ≤ 0.06 are shown. Bars represent standard deviation (SD) values. Proteins that only showed significant association with PFS when non‐normalised PEA data were used are presented in Fig. . Please note that pat. #114 was excluded in these analyses. For LOD of the proteins, see Table . (C) The expression of individual proteins from the PEA analyses was plotted with linearised values against PFS in linear regression analyses (see Section ). The table indicates the Pearson correlation coefficient alongside P ‐value for non‐normalised samples. Please, note that pat. #114 was excluded in these analyses. Presented data in A–C are from one PEA profiling of one biological isolate of EVs from plasma of the individual patients. (D) Western blot profiling of SYND‐1 and GZMH in EVs isolated from plasma samples of mUC patients at day 21. SYND‐1 and GZMH were profiled without normalising for the amount of EVs in the different samples. The fold expression of SYND‐1 relative to pat. #107 is given with (fold norm) or without (fold) normalisation for the number of EVs analysed. The densitometric quantification of SYND‐1 (without normalisation) is presented in Fig. . Data shown are from one western blot analysis of one biological isolate of EVs from the individual plasma samples of the patients.

    Journal: Molecular Oncology

    Article Title: Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome

    doi: 10.1002/1878-0261.13288

    Figure Lengend Snippet: Protein profiling of extracellular vesicles in relation to progression‐free survival. Extracellular vesicles (EVs) isolated from plasma samples from metastatic urothelial cancer (mUC) patients at day 21 were subjected to proximity extension assay (PEA) protein profiling with the Oncology II ® assay (see Section ). (A) Rank regression analyses of protein signatures in EVs related to progression‐free survival (PFS) [long (green) vs short (red)] of the study population. The qlucore software rank regression tool was used with P ≤ 0.05, and protein signatures were sorted without ( left panel ) or with ( right panel ) the number of EVs applied in the PEA profiling as elimination factor (see Section ). For description of the processing of the PEA data prior to the Qlucore analyses with respect to samples showing protein expression below lower limit of detection (LOD) see Sections and . The PEA data were also analysed with the XGBoost integrated tool of the qlucore software (see Section ). The proteins sorted out by this approach and that also were revealed by univariate rank regression analyses are indicated with (*). (B) The normalized protein expression (NPX) values of individual proteins from (A) were analysed in EVs from plasma of patients with short (≤ 138 days) or long (> 138 days) PFS ( top panel ) or after normalising for the number of EVs used in the PEA profiling ( bottom panel ). Only proteins that were statistically significant using t ‐test (see Section ) at P ≤ 0.05 and ≤ 0.06 are shown. Bars represent standard deviation (SD) values. Proteins that only showed significant association with PFS when non‐normalised PEA data were used are presented in Fig. . Please note that pat. #114 was excluded in these analyses. For LOD of the proteins, see Table . (C) The expression of individual proteins from the PEA analyses was plotted with linearised values against PFS in linear regression analyses (see Section ). The table indicates the Pearson correlation coefficient alongside P ‐value for non‐normalised samples. Please, note that pat. #114 was excluded in these analyses. Presented data in A–C are from one PEA profiling of one biological isolate of EVs from plasma of the individual patients. (D) Western blot profiling of SYND‐1 and GZMH in EVs isolated from plasma samples of mUC patients at day 21. SYND‐1 and GZMH were profiled without normalising for the amount of EVs in the different samples. The fold expression of SYND‐1 relative to pat. #107 is given with (fold norm) or without (fold) normalisation for the number of EVs analysed. The densitometric quantification of SYND‐1 (without normalisation) is presented in Fig. . Data shown are from one western blot analysis of one biological isolate of EVs from the individual plasma samples of the patients.

    Article Snippet: The PEA data were also explored using a machine learning algorithm XGBoost (Extreme Gradient Boosting, Qlucore integrated tool; see https://xgboost.readthedocs.io/en/latest/ #) to build classifier models.

    Techniques: Isolation, Ii Assay, Software, Expressing, Standard Deviation, Western Blot

    Profiling of extracellular vesicles to reveal putative protein signatures in relation to treatment response. Extracellular vesicles (EVs) isolated from plasma samples from metastatic urothelial cancer (mUC) patients at day 8 post‐treatment were subjected to proximity extension assay (PEA) protein profiling with the Oncology II ® assay as described in Section . Please note that for pat. #110, fractions 7–10 were analysed, while for all the other patients, fractions 6–10 were examined. (A) Rank regression analyses of protein signatures ( P ≤ 0.05) in EVs related to best response of the patients evaluated by computerised tomography (CT) (Fig. B) are presented. The analyses were carried out as in Fig. with the number of EVs analysed applied as an elimination factor (see Section ). The PEA data were also analysed with the XGBoost integrated tool of the qlucore software (see Section ) at day 21. Star (*) indicates that FASLG, which was revealed by univariate analyses, also was identified with this method. (B) The linear expression of indicated proteins in individual EV samples at day 8 and 21 was plotted against best CT response without normalisation for the number of EVs analysed. The line indicates results from the linear regression analyses. The Pearson correlation coefficient is given alongside the P ‐value. The lower limit of detection (LOD) and RIPA negative control values are presented in Table . Please note that pat. #114 was excluded in these analyses (see Section ).

    Journal: Molecular Oncology

    Article Title: Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome

    doi: 10.1002/1878-0261.13288

    Figure Lengend Snippet: Profiling of extracellular vesicles to reveal putative protein signatures in relation to treatment response. Extracellular vesicles (EVs) isolated from plasma samples from metastatic urothelial cancer (mUC) patients at day 8 post‐treatment were subjected to proximity extension assay (PEA) protein profiling with the Oncology II ® assay as described in Section . Please note that for pat. #110, fractions 7–10 were analysed, while for all the other patients, fractions 6–10 were examined. (A) Rank regression analyses of protein signatures ( P ≤ 0.05) in EVs related to best response of the patients evaluated by computerised tomography (CT) (Fig. B) are presented. The analyses were carried out as in Fig. with the number of EVs analysed applied as an elimination factor (see Section ). The PEA data were also analysed with the XGBoost integrated tool of the qlucore software (see Section ) at day 21. Star (*) indicates that FASLG, which was revealed by univariate analyses, also was identified with this method. (B) The linear expression of indicated proteins in individual EV samples at day 8 and 21 was plotted against best CT response without normalisation for the number of EVs analysed. The line indicates results from the linear regression analyses. The Pearson correlation coefficient is given alongside the P ‐value. The lower limit of detection (LOD) and RIPA negative control values are presented in Table . Please note that pat. #114 was excluded in these analyses (see Section ).

    Article Snippet: The PEA data were also explored using a machine learning algorithm XGBoost (Extreme Gradient Boosting, Qlucore integrated tool; see https://xgboost.readthedocs.io/en/latest/ #) to build classifier models.

    Techniques: Isolation, Ii Assay, Tomography, Software, Expressing, Negative Control